Palisade Bio, Inc
Palisade Bio, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for gastrointestinal and inflammatory diseases. Its lead program, PALI-2108, is being advanced through preclinical and clinical development with external research, manufacturing, and regulatory partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePALI-2108 is the company's lead drug candidate for gastrointestinal and inflammatory indications.
Internal and outsourced activities to advance PALI-2108 through trials and regulatory steps.
Development rights and collaboration arrangements tied to the PALI-2108 program.
Customers
Palisade Bio does not sell commercial products today; its primary counterparties are clinical trial participants, investigators, contract research organizations, contract manufacturers, and regulatory agencies. If approved in the future, its end customers would be physicians, insurers, payors, and patients in the gastrointestinal disease market.
Investigators, CROs, and trial sites that execute and oversee PALI-2108 studies.
API suppliers and third-party manufacturers that produce clinical trial materials.
Health Canada, FDA, and other agencies that review trial and product approvals.
Physicians, insurers, payors, and patients who would adopt PALI-2108 if commercialized.
Strategy
Palisade Bio's strategy is to advance PALI-2108 through clinical development, generate regulatory data, and position the asset for later-stage development and potential commercialization. The company relies on external partners for manufacturing and clinical operations, while preserving capital through collaboration, licensing, and financing activities.
Clinical proof-of-concept is the main value driver for a single-asset biotech.
The company depends on third parties for API supply, trial conduct, and cGMP production.
Development programs require approvals and capital before any commercial revenue exists.
Geography
The company is headquartered in the United States and conducts its development activities through a cross-border clinical footprint. Its current clinical work includes studies in Canada, with planned U.S. clinical development subject to FDA clearance, which makes regulatory timing and trial execution in both countries strategically important.
Risks
Palisade Bio faces the classic risks of a single-asset clinical-stage biotech: trial failure, regulatory setbacks, and the need for repeated financing before any product revenue exists. Its dependence on a small number of suppliers, CROs, and licensing rights adds operational and legal concentration risk, while Nasdaq listing compliance and capital access remain important financial risks.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company depends on successful Phase 1/2 development of PALI-2108 to create value.
Exposure: Lead asset PALI-2108
- Financing riskImpact: HighLikelihood: High
Development spending exceeds current operating cash generation and requires external funding.
Exposure: Clinical development runway
- Regulatory approval and data acceptance riskImpact: HighLikelihood: Medium
Authorities may not accept foreign trial data or may require additional studies.
Exposure: Canada and U.S. trial pathway
- Supply chain and manufacturing concentrationImpact: HighLikelihood: Medium
The company relies on two qualified API suppliers and third-party manufacturers.
Exposure: Clinical trial materials and API supply
- License agreement dependenceImpact: HighLikelihood: Medium
PALI-2108 rights depend on the Giiant license arrangement and related obligations.
Exposure: Intellectual property and commercialization rights
Accounting
Judgemental itemsTrial, CRO, and manufacturing costs are often recognized before invoices arrive.
Impact: Can shift operating expense timing between quarters
The Giiant license includes a contingent consideration obligation measured at fair value.
Impact: Non-cash remeasurement can affect reported net loss
Warrants and related financing features may require valuation adjustments.
Impact: Can create volatility in other income/expense
Clinical trial and regulatory spending is lumpy and milestone-driven.
Impact: Makes period-to-period comparisons less comparable
Similar listed companies
Publicly listed companies with a comparable business focus.
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Rallybio Corp
RLYB · Pharmaceutical Preparations
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Rani Therapeutics Holdings, Inc.
RANI · Pharmaceutical Preparations
Last updated: 24/09/2026